Recent studies have demonstrated that Wnt5a could induce activation of Rac1 in leukemia cells of patients with CLL via a ROR1-dependent pathway [1], which could not be inhibited by ibrutinib [2]. The gene discussed is RAC1; the disease is B-cell chronic lymphocytic leukemia.